Juvena Therapeutics Contact

Team

Scientists, drug developers and engineers, decoding the secretome together.

One team, one mission: regenerate tissues to rejuvenate lives.

Leadership

Management

Julie Anne Smith

Julie Anne Smith

Chief Executive Officer and Director

Read biography of Julie Anne Smith
Jeremy O’Connell, PhD

Jeremy O’Connell, PhD

Chief Scientific Officer and Co-Founder

Read biography of Jeremy O’Connell, PhD
Banmeet Anand, PhD

Banmeet Anand, PhD

Senior Vice President of Drug Development

Read biography of Banmeet Anand, PhD
Colin Hislop, MD

Colin Hislop, MD

Senior Vice President of Clinical Development

Read biography of Colin Hislop, MD
Bek Madjidov

Bek Madjidov

Vice President of Finance and Operations

Read biography of Bek Madjidov
Thach Mai, PhD

Thach Mai, PhD

Senior Director of Discovery & Platform

Read biography of Thach Mai, PhD
Priya Handa, PhD

Priya Handa, PhD

Senior Director, Translational Biology & Pharmacology

Read biography of Priya Handa, PhD
Zhihua Li, PhD

Zhihua Li, PhD

Senior Director, Bioanalytical Science

Read biography of Zhihua Li, PhD
Julie Seal, MBA

Julie Seal, MBA

Senior Director, Program Management

Read biography of Julie Seal, MBA

Leadership biographies

Leadership

Julie Anne Smith

Chief Executive Officer and Director

LinkedIn profile of Julie Anne Smith

Julie Anne Smith is the Chief Executive Officer and Director at Juvena Therapeutics. She brings over 20 years of life sciences industry experience to Juvena, with a proven track record of leading private and public biotechnology companies through the successful development and commercialization of therapeutics for rare and orphan diseases.

Prior to joining Juvena, Ms. Smith served as CEO and director of Nuvig Therapeutics and as President and CEO of ESCAPE Bio. Her executive leadership experience also includes serving as President and CEO of Raptor Pharmaceuticals, until its acquisition by Horizon Pharmaceuticals, and as Chief Commercial Officer of Enobia Pharmaceuticals until its acquisition by Alexion Pharmaceuticals. Earlier in her career, Ms. Smith held various industry roles of increasing responsibility at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb.

In addition to her executive roles, she currently serves on the boards of directors of Stoke Therapeutics and Exelixis, Inc. She previously served on the board of directors of Audentes Therapeutics, Inc., as well as the Health and Emerging Companies Section Governing Boards of the Biotechnology Industry Organization (BIO).

Ms. Smith holds a B.S. in biological and nutritional sciences from Cornell University.

Leadership

Jeremy O’Connell, PhD

Chief Scientific Officer and Co-Founder

LinkedIn profile of Jeremy O’Connell, PhD

As Chief Scientific Officer and Co-Founder of Juvena Therapeutics, Dr. Jeremy O’Connell oversees research strategy, pre-clinical science and early development, and intellectual property efforts.

Dr. O’Connell has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches. His work has resulted in numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards.

Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical School in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system. He also gained valuable experience during his time in industry.

Dr. O’Connell’s expertise in proteomics and systems biology was acquired through his Ph.D. from UT Austin and his postdoctoral work at Harvard.

Leadership

Banmeet Anand, PhD

Senior Vice President of Drug Development

LinkedIn profile of Banmeet Anand, PhD

Dr. Banmeet Anand’s more than 20 years experience in the discovery and development of antibodies encompasses fusion proteins, naked, ADCs and bi-specific antibodies;  small molecules, and cellular therapies (NK-T, CAR-T) at  biotechs and large pharma including Harpoon (a subsidiary of Merck & Co. inc.), Astellas and  Genentech.

Leadership

Colin Hislop, MD

Senior Vice President of Clinical Development

LinkedIn profile of Colin Hislop, MD

As SVP Clinical Development, Dr. Colin Hislop leads Juvena’s clinical-stage drug candidates. His 38-year tenure in drug development and life sciences spans multinational roles across therapeutic areas at companies including Lilly (Eli Lilly and Company), Procter & Gamble Pharmaceuticals, Peninsula Therapeutics, CV Therapeutics, Versartis Inc. Anthera Pharmaceuticals and most recently Eiger BioPharmaceuticals. His expertise encompasses early and late-stage clinical development as well as the successful prosecution of multiple drug approvals.

Leadership

Bek Madjidov

Vice President of Finance and Operations

LinkedIn profile of Bek Madjidov

Bek Madjidov leads finance, people and culture, IT and business operations. He supports the CEO and scientific leadership on corporate strategy, capital planning, fundraising, investor relations, partnerships and organizational growth. Bek brings nearly two decades of finance and operations experience across biopharma, including finance leadership roles at Genentech/Roche supporting R&D, manufacturing and supply chain organizations. Earlier in his career, he held roles of increasing responsibility at Autodesk and Bio-Rad Laboratories.

Leadership

Thach Mai, PhD

Senior Director of Discovery & Platform

LinkedIn profile of Thach Mai, PhD

Dr. Thach Mai joined Juvena Therapeutics as a Stem Cell Biologist and Bioinformatician to lead the validation and discovery of the key rejuvenating protein factors in Juvena Therapeutics’ complex embryonic secretome cocktail and develop and improve Juvena’s HTS platform for protein therapeutic discovery.

Leadership

Priya Handa, PhD

Senior Director, Translational Biology & Pharmacology

LinkedIn profile of Priya Handa, PhD

Priya Handa, PhD has over 15 years of experience in basic, preclinical and translational research spanning multiple disease areas including metabolic, hepatic, renal and ocular, among others. Prior to joining Juvena Therapeutics, Priya was a Principal Scientist and a team leader at Surrozen focused on tissue regeneration using their antibody platform in diseases with an unmet need. There, she championed several early stage discovery programs and was a key contributor to the Inflammatory Bowel Disease (IBD) program which is currently in Phase I clinical trials.

Leadership

Zhihua Li, PhD

Senior Director, Bioanalytical Science

Dr. Li is a biologist with a multidisciplinary background in Biochemistry, Immunology, Cell and Molecular Biology, with 7 years of research experience in academia and 4 years in industry. He joined Juvena Therapeutics as a Protein Engineering Scientist to build protein expression and purification pipelines and to improve Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.

Leadership

Julie Seal, MBA

Senior Director, Program Management

LinkedIn profile of Julie Seal, MBA

Julie Seal is a program and portfolio management leader with a track record of advancing complex biopharmaceutical programs from early development through commercialization. She brings deep experience across biologics and small molecules, leading cross-functional efforts spanning nonclinical, translational, clinical, CMC, regulatory, and commercial functions.

Governance

Board of directors

Cristina Ghenoiu, PhD

Cristina Ghenoiu, PhD

Partner · Mubadala Capital

Read biography of Cristina Ghenoiu, PhD
Ben Hemani, MEM

Ben Hemani, MEM

Founding Partner · Bison Ventures

Read biography of Ben Hemani, MEM
Steven James, MBA

Steven James, MBA

Independent Director

Read biography of Steven James, MBA
Stephen Juelsgaard, DVM, JD

Stephen Juelsgaard, DVM, JD

Independent Director

Read biography of Stephen Juelsgaard, DVM, JD
Laura Lande-Diner, PhD

Laura Lande-Diner, PhD

Managing Partner · Jefferson Life Sciences

Read biography of Laura Lande-Diner, PhD
Jeremy O’Connell, PhD

Jeremy O’Connell, PhD

Co-Founder and Chief Scientific Officer

Read biography of Jeremy O’Connell, PhD
Julie Anne Smith

Julie Anne Smith

Chief Executive Officer and Director

Read biography of Julie Anne Smith
Hanadie Yousef, PhD

Hanadie Yousef, PhD

Co-Founder and Director

Read biography of Hanadie Yousef, PhD

Board biographies

Board of directors

Cristina Ghenoiu, PhD

Partner · Mubadala Capital

LinkedIn profile of Cristina Ghenoiu, PhD

Cristina Ghenoiu, Ph.D., is a Partner in Mubadala Capital’s venture business, focusing on biotechnology investments, with 15+ years of experience across public markets, crossover and venture investing, company creation, and operations. Since joining Mubadala in 2023, she has led the firm’s investments in Capstan Therapeutics (acquired by AbbVie for up to $2.1B in 2025) and in Electra Therapeutics’ Series C and $350M IPO (ETRA).

During her time at Longitude and RA Capital, she played a key role in financing companies such as Vaxcyte (PCVX), CuraSen, and Molecular Templates (MTEM), and venture builds including 89bio (ETNB; acquired by Roche for up to $3.5B in 2025), Capacity Bio, GIVAX, and Superluminal Medicines. She is a scientific co-founder of Rivus Pharmaceuticals, and she helped spin out Epirium Bio and raise its $85M Series A before serving as its SVP, R&D Operations. She began her career in biotech equity research at TD Cowen.

She holds a Ph.D. from Weill Cornell, completed a postdoc at The Rockefeller University, and earned a B.A. in Biochemistry from Mount Holyoke College, with High Honors for her computational quantum chemistry thesis.

Board of directors

Ben Hemani, MEM

Founding Partner · Bison Ventures

LinkedIn profile of Ben Hemani, MEM

Ben Hemani is a member of the Board of Directors for Juvena Therapeutics and a Founding Partner at Bison Ventures, where he orchestrates investments at the intersection of AI-enabled physical innovation, frontier tech, and climate sustainability.

Mr. Hemani is a venture investor and engineer-turned-strategist with extensive expertise managing early-to-growth stage portfolios across hard-tech and life science domains.

Prior to co-founding Bison Ventures, he focused on frontier technology and health investments at Cascade Asset Management Company, overseeing the family and foundation assets of Bill Gates. His institutional history also includes serving as a principal investor at Braemar Energy Ventures, where he led prominent climate tech deals including early-stage backing for ChargePoint. Throughout Ben’s investment career he has partnered with 8 unicorns (and counting)!

Mr. Hemani holds a Bachelor of Arts in Engineering Sciences modified with Economics from Dartmouth College, alongside a Master of Engineering Management (MEM) from the Thayer School of Engineering at Dartmouth. He maintains an active institutional tie to his alma mater as a member of the Thayer School of Engineering Dean's Council.

Board of directors

Steven James, MBA

Independent Director

LinkedIn profile of Steven James, MBA

Steven James is an Independent Director at Juvena Therapeutics.

Mr. James is a biopharmaceutical leader with over 35 years of experience, having been involved in building and leading numerous successful companies and overseeing the discovery and development of important approved drug products.

Mr. James was most recently president, Chief Executive Officer, and director of Pionyr Immunotherapeutics. Gilead acquired 49.9% of Pionyr and Pionyr was acquired by Ikena Oncology (now Inmagene). Previously, he served as president, Chief Executive Officer, and director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, he was president, Chief Executive Officer, and director of KAI Pharmaceuticals, which was acquired by Amgen. Earlier in his career, he held leadership positions at Exelixis, Sunesis Pharmaceuticals, and Ionis Pharmaceuticals, and began his career at Eli Lilly.

In addition to his current directorships, Mr. James was formerly the chairman of Antiva Biosciences, and a director of Allakos Inc. (acquired by Concentra), Ocera Inc. (acquired by Mallinckrodt), and Cascadian Therapeutics (acquired by Seattle Genetics).

He currently serves as a director of Rondo Therapeutics, Ventus Therapeutics, and Lyterian Therapeutics and is an executive advisor to Vedana Therapeutics. Mr. James holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University.

Board of directors

Stephen Juelsgaard, DVM, JD

Independent Director

LinkedIn profile of Stephen Juelsgaard, DVM, JD

Stephen Juelsgaard, DVM, JD, is an Independent Director at Juvena Therapeutics. A distinguished Stanford Law School alumnus (JD '82) and former adjunct lecturer, Dr. Juelsgaard is the founding benefactor of the Juelsgaard Intellectual Property and Innovation Clinic.

Dr. Juelsgaard joined Genentech, Inc. in 1985 and retired from the company in 2009. He previously served as executive vice president, secretary and chief compliance officer of Genentech. Prior to those roles, he served in a variety of legal roles of increasing responsibility and was the company’s representative on the board of directors of the California Healthcare Institute. Prior to joining Genentech, he was an associate with the law firm Wilson Sonsini Goodrich & Rosati and practiced as a veterinarian.

He currently serves as Chairman of the board of directors of AltruBio, a protein-based therapeutic company targeting ulcerative colitis and other autoimmune and immune-mediated inflammatory diseases. He served for 13 years as a board member of the California Institute for Regenerative Medicine, a state agency where he was the chair of a number of the Institute's committees. He is a past member of the board of directors of Ivivi Health Sciences LLC and Rio Grande Neurosciences, Inc. He is a trustee of the African Wildlife Foundation, an African based conservation organization.

He received his Doctor of Veterinary Medicine degree from Iowa State University, a Masters Degree in Veterinary Clinical Sciences from Iowa State University, and a law degree from Stanford Law School. He endowed the position of the Dean of Veterinary Medicine at Iowa State University.

Board of directors

Laura Lande-Diner, PhD

Managing Partner · Jefferson Life Sciences

LinkedIn profile of Laura Lande-Diner, PhD

Laura Lande-Diner, Ph.D., is a Director at Juvena Therapeutics and is the Managing Partner of Jefferson Life Sciences, the life sciences investment arm of Jefferson River Capital.

Dr. Lande-Diner brings a unique combination of scientific expertise, operating leadership, and strategic investment experience. She was previously a founding executive of Satellite Bio where she served as Chief Business Officer and President. She was also a founding team member of Valo Health where she helped shape the company’s early strategy and executed foundational business development partnerships. Prior to Valo, Laura was a member of the Origination team at Flagship Pioneering, where she contributed to the founding and early development of four life sciences companies.

She currently serves as a member of the Board of Directors at Fesarius Therapeutics. Dr. Lande-Diner holds a Ph.D. in Epigenetics and Molecular Biology from the Hebrew University of Jerusalem Medical School and completed postdoctoral research in Circadian Biology at Harvard Medical School, where she served as an Instructor in Neurobiology. She serves as a mentor for the MIT-Faculty Founder Initiative and the Harvard Business School Foundry Catalyst and she is a member of the Museum of Science, Boston, Board of Trustees.

Board of directors

Hanadie Yousef, PhD

Co-Founder and Director

LinkedIn profile of Hanadie Yousef, PhD

Dr. Hanadie Yousef is a Director at Juvena Therapeutics and a Co-Founder of the company, where she previously served as CEO, CFO, Board Chair and Executive Advisor.

Dr. Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity with over two decades of experience in biomedical research.

Under Dr. Yousef’s leadership, Juvena secured over $105M in venture capital, non-dilutive grants, and partnerships, and developed a proprietary pipeline of tissue-restorative biologics as well as securing a discovery partnership with Eli Lilly. Her research led to multiple patents and garnered support from NIH, NSF, SPARK, and CIRM. She was named to the 2025 Mayfield AI Industry Leader List and designated a World Economic Forum 2024 Technology Pioneer. Her accolades include FierceBiotech’s "Fiercest Women in Life Sciences," Business Insider’s "30 Leaders Under 40," Endpoints News’ "20(+2) Under 40," the San Francisco Business Times "Women Who Lead in Life Sciences," and the Biocom Catalyst Award.

She earned her B.S. summa cum laude from Carnegie Mellon University, her PhD from UC Berkeley as an NSF Fellow, and completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her career in biomedical research began early with research positions at Regeneron starting at age 15 and a neuroscience internship at Genentech.

Board observers

Pablo Cabral

Pablo Cabral

Board observer · Eli Lilly

Read biography of Pablo Cabral
Joseph Miletich, MD, PhD

Joseph Miletich, MD, PhD

Board observer · SAB Chairman

Read biography of Joseph Miletich, MD, PhD
Craig Nemiroff

Craig Nemiroff

Board observer · MAK Capital

Read biography of Craig Nemiroff
Tobias Schmid, PhD

Tobias Schmid, PhD

Board observer · Mubadala Capital

Read biography of Tobias Schmid, PhD
Julia Schrameier

Julia Schrameier

Board observer · Manta Ray

Patrick Zhang, MBA

Patrick Zhang, MBA

Board observer · Horizons Ventures

Read biography of Patrick Zhang, MBA

Board observer biographies

Board observer

Pablo Cabral

Board observer · Eli Lilly

Pablo is an Executive Director in Cardiometabolic Research at Eli Lilly, where he holds a dual role spanning external innovation and internal research and development within the Mobility and Healthy Aging Research pillar.

Prior to Lilly, he spent several years in drug development in the cardiometabolic therapeutic area at Johnson & Johnson and at Merck in South San Francisco.

He earned his medical degree from the National University of Córdoba in Argentina, and began his career in academic research as a postdoctoral fellow and junior faculty member in the Department of Physiology and Biophysics at Case Western Reserve University, focusing on kidney and vascular biology.

Board observer

Joseph Miletich, MD, PhD

Board observer · SAB Chairman

LinkedIn profile of Joseph Miletich, MD, PhD

Joseph Miletich, MD, PhD, is a board observer and former senior executive in biopharmaceutical research and development.

Dr. Miletich is a distinguished physician-scientist and academic leader with more than 20 years of combined executive experience at Merck and Amgen leading programs through Discovery Research, Preclinical Development, and Translational Medicine, alongside a 17-year academic career as Professor of Medicine and Pathology at Washington University.

Most recently, Dr. Miletich served as senior vice president of research sciences at Merck Research Laboratories, prior to which he was senior vice president of research and development at Amgen. Earlier in his career, he completed his clinical training in internal medicine at the University of California, San Francisco, and joined the faculty at Washington University, where he headed the Division of Laboratory Medicine and the combined laboratories of the Barnes-Jewish Hospital system.

Since retiring from Merck he has advised numerous investment funds, biotechs, pharmas, and not-for-profits. He maintains a leadership role with Aurita Bioscience Corporation.

Dr. Miletich received his M.D. and Ph.D. degrees from Washington University in St. Louis. He completed his clinical training in internal medicine at the University of California in San Francisco and pursued subspecialty training in clinical hematology and laboratory medicine at Washington University.

Board observer

Craig Nemiroff

Board observer · MAK Capital

LinkedIn profile of Craig Nemiroff

Craig Nemiroff is a board observer at Juvena Therapeutics and currently serves as Managing Director and Analyst at MAK Capital, an investment advisory firm headquartered in New York.

With nearly 20 years of experience spanning public and private financial markets, Mr. Nemiroff is an investment strategist and life sciences advisor. Since joining MAK Capital in 2016, he has guided private equity investments and venture capital strategy focused on clinical-stage biopharmaceutical ventures. His earlier background in corporate development and finance includes serving as Director of Business Development at MRU Holdings, Manager of Corporate Development at Capital One Financial, and investment analyst at One East Partners. He began his career practicing corporate law with Davis Polk & Wardwell in New York and providing strategy consulting at the Boston Consulting Group.

He currently serves on the Board of Directors for various biotechnology and healthcare technology enterprises, including Noveome Biotherapeutics, MARAbio Systems, and Trailhead Biosystems.

He earned a Juris Doctor from Yale Law School and holds an A.B. in Economics from Princeton University.

Board observer

Tobias Schmid, PhD

Board observer · Mubadala Capital

LinkedIn profile of Tobias Schmid, PhD

Dr. Tobias Schmid, PhD, is a board observer at Juvena Therapeutics and currently serves as a Principal on Mubadala Capital’s Ventures investment team based in San Francisco.

Dr. Schmid is a neuroscientist, early-stage biotechnology investor, and new venture builder with extensive experience bridging academic discovery and venture creation. Since joining Mubadala Capital in 2023, he has played a critical role in shaping the firm’s healthcare investment strategy and company creation efforts. Prior to his tenure at Mubadala, he focused on early-stage venture formation as a Swanson Fellow at The Column Group. Dr. Schmid is a dedicated advocate for expanding the pipeline of diverse talent in the biotechnology ecosystem, serving as a co-founder of Nucleate Bay Area and as a member of the Board of Directors for Biotech Partners, a non-profit organization providing STEM education and mentorship to underrepresented students. He also serves as an Expert in Residence at UC Berkeley’s Life Sciences Entrepreneurship Center (LSEC).

He currently serves as a board observer for Ollin Biosciences, Tenvie Therapeutics, and Pretzel Therapeutics. Dr. Schmid received his Ph.D. in Neuroscience from the University of California, Berkeley. He also holds a Bachelor of Science in Neuroscience and a Bachelor of Arts in Spanish from the University of Florida.

Board observer

Patrick Zhang, MBA

Board observer · Horizons Ventures

LinkedIn profile of Patrick Zhang, MBA

Patrick Zhang is a Board Observer at Juvena Therapeutics and leads biotechnology and healthcare investments at Horizons Ventures.

Mr. Zhang is a chemical engineer by training and an experienced healthcare investor, with over a decade of experience spanning biotechnology, medical technology, and emerging healthcare technologies. At Horizons Ventures, he has led and managed investments in more than 20 healthcare and biotechnology companies globally, with a focus on innovative therapeutics, medical devices, and emerging technology platforms. He has served on the boards of multiple portfolio companies, supporting their strategic development, financing, and corporate transactions.

Prior to joining Horizons Ventures, Mr. Zhang was an investment banker at Morgan Stanley, advising clients on capital raising and cross-border mergers and acquisitions.

Mr. Zhang holds an MBA from Columbia Business School and a B.S. in Chemical Engineering from the University of California, Los Angeles (UCLA).

Scientific team

Discovery, pharmacology, protein science, data science and operations

The people who run JuvNET every day, from secretome proteomics and machine learning to in vivo pharmacology and protein production.

Vengadeshprabhu Karuppa Gounder, PhD

Vengadeshprabhu Karuppa Gounder, PhD

Senior Scientist II - Pharmacology

Sharon Louie, PhD

Sharon Louie, PhD

Senior Scientist II - Pharmacology

Ritwik Datta, PhD

Ritwik Datta, PhD

Senior Scientist I

Rohit Jadhav, PhD

Rohit Jadhav, PhD

Senior Scientist II

Mingyu Chung, PhD

Mingyu Chung, PhD

Senior Scientist I - Single Cell Genomics

Zhi (Zack) Zheng, PhD

Zhi (Zack) Zheng, PhD

Scientist I

Danielle Yi

Danielle Yi

Scientist I

Trang Vuong

Trang Vuong

Scientist I

Munir Yousef, MS

Munir Yousef, MS

Senior Bioinformatics Analyst

Ashil Koranne

Ashil Koranne

Associate Scientist

Megan Smith

Megan Smith

Associate Scientist

Annie Yang, MS

Annie Yang, MS

Senior Research Associate

Sarah Tang

Sarah Tang

Senior Research Associate

Jonathan Gaffney

Jonathan Gaffney

Research Associate

Theodore Yu

Theodore Yu

Research Associate

Jamie Romero

Jamie Romero

Associate Director, Operations

Natalie Ploof

Natalie Ploof

Lab Manager

Careers

Be part of the team decoding secreted proteins.

Open rolesGeneral inquiry